Dr. MiltieAtlas by Dr. Miltie™Nationwide Grant Intelligence
Verification Pending — official Grants.gov candidate (posted)
HT942526VRPCTA

DoW Vision, Clinical Trial Award

Official Grants.gov opportunity HT942526VRPCTA from Teresa M Parker-Reeser Grants Officer. Requires full eligibility, amount, controlling deadline, award-type and duplication QA before publication.

FundingApplicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Deadline2026-11-12 (official deadline clock time and time zone must be checked in NOFO)
Last verifiedAtlas review
Required next actionReview the official full announcement, amendments and submission portal requirements before applying.

Broad Eligibility

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Official funding announcement — preliminary draft

Funder: Teresa M Parker-Reeser Grants Officer

Opportunity number: HT942526VRPCTA

Official listed status: posted

Closing information: 2026-11-12 (official deadline clock time and time zone must be checked in NOFO)

Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.

Applicant categories in federal synopsis: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

Federal synopsis

Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas.   Distinctive Features: ·       For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding. Refer to Attachment 7: Regulatory Strategy for further details. ·       Scored peer review criteria include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication. ·       Programmatic review criteria include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health. https://cdmrp.health.mil/pubs/press/2026/vrppreann

Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.

Official Grants.gov opportunity and NOFO

Source verificationOfficial government source · www.grants.govAtlas last verified this record during its latest review. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗